Literature DB >> 18382469

Additive effects of statin and dipyridamole on cerebral blood flow and stroke protection.

Hyung-Hwan Kim1, Naoki Sawada, Guray Soydan, Ho-Seong Lee, Zhipeng Zhou, Seo-Kyoung Hwang, Christian Waeber, Michael A Moskowitz, James K Liao.   

Abstract

Recent studies suggest that dipyridamole (DP) may exert stroke protective effects beyond platelet inhibition. The purpose of this study is to determine whether statin and DP could enhance stroke protection through nitric oxide (NO)-dependent vascular effects. Mice were pretreated with DP (10 to 60 mg/kg, q 12 h, 3 days) alone or in combination with a statin (simvastatin; 0.1 to 20 mg/kg per day, 14 days) before transient intraluminal middle cerebral artery occlusion. Although simvastatin (1 mg/kg per day, 14 days) increased endothelial NO synthase (eNOS) activity by 25% and DP (30 mg/kg, q12 h, 3 days) increased aortic cGMP levels by 55%, neither statin nor DP alone, at these subtherapeutic doses, increased absolute cerebral blood flow (CBF) or conferred stroke protection. However, the combination of subtherapeutic doses of simvastatin and DP increased CBF by 50%, decreased stroke volume by 54%, and improved neurologic motor deficits, all of which were absent in eNOS-deficient mice. In contrast, treatment with aspirin (10 mg/kg per day, 3 days) did not augment the neuroprotective effects of DP and/or simvastatin. These findings indicate that statin and DP exert additive NO-dependent vascular effects and suggest that the combination of statin and DP has greater benefits in stroke protection than statin alone through vascular protection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18382469      PMCID: PMC2662038          DOI: 10.1038/jcbfm.2008.24

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  37 in total

1.  High-dose atorvastatin after stroke or transient ischemic attack.

Authors:  Pierre Amarenco; Julien Bogousslavsky; Alfred Callahan; Larry B Goldstein; Michael Hennerici; Amy E Rudolph; Henrik Sillesen; Lisa Simunovic; Michael Szarek; K M A Welch; Justin A Zivin
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

2.  Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: in vitro and in vivo/ex vivo studies.

Authors:  Barsom Aktas; Andrea Utz; Petra Hoenig-Liedl; Ulrich Walter; Joerg Geiger
Journal:  Stroke       Date:  2003-01-30       Impact factor: 7.914

3.  Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine.

Authors:  Z Huang; P L Huang; J Ma; W Meng; C Ayata; M C Fishman; M A Moskowitz
Journal:  J Cereb Blood Flow Metab       Date:  1996-09       Impact factor: 6.200

4.  Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

Authors: 
Journal:  Lancet       Date:  2000-01-22       Impact factor: 79.321

5.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

Review 6.  Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Gregory W Albers; Pierre Amarenco; J Donald Easton; Ralph L Sacco; Philip Teal
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

7.  Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline.

Authors:  Ralph L Sacco; Robert Adams; Greg Albers; Mark J Alberts; Oscar Benavente; Karen Furie; Larry B Goldstein; Philip Gorelick; Jonathan Halperin; Robert Harbaugh; S Claiborne Johnston; Irene Katzan; Margaret Kelly-Hayes; Edgar J Kenton; Michael Marks; Lee H Schwamm; Thomas Tomsick
Journal:  Circulation       Date:  2006-03-14       Impact factor: 29.690

8.  Mechanism of the antiplatelet action of dipyridamole in whole blood: modulation of adenosine concentration and activity.

Authors:  P Gresele; J Arnout; H Deckmyn; J Vermylen
Journal:  Thromb Haemost       Date:  1986-02-28       Impact factor: 5.249

9.  Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination.

Authors:  Yumei Ye; Yu Lin; Regino Perez-Polo; Ming-He Huang; Michael G Hughes; David J McAdoo; Saraswathy Manickavasagam; Barry F Uretsky; Yochai Birnbaum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-04-06       Impact factor: 4.733

10.  Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.

Authors:  M Endres; U Laufs; Z Huang; T Nakamura; P Huang; M A Moskowitz; J K Liao
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

View more
  23 in total

Review 1.  Statins and cerebral hemodynamics.

Authors:  Sotirios Giannopoulos; Aristeidis H Katsanos; Georgios Tsivgoulis; Randolph S Marshall
Journal:  J Cereb Blood Flow Metab       Date:  2012-08-29       Impact factor: 6.200

2.  Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats.

Authors:  Nikkita Puri; Vinita Mohey; Manjinder Singh; Tajpreet Kaur; Devendra Pathak; Harpal Singh Buttar; Amrit Pal Singh
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-01-04       Impact factor: 3.000

Review 3.  Current therapeutic strategies to mitigate the eNOS dysfunction in ischaemic stroke.

Authors:  Kirtiman Srivastava; Philip M W Bath; Ulvi Bayraktutan
Journal:  Cell Mol Neurobiol       Date:  2011-12-25       Impact factor: 5.046

4.  Mdivi-1 Protects Against Ischemic Brain Injury via Elevating Extracellular Adenosine in a cAMP/CREB-CD39-Dependent Manner.

Authors:  Mei Cui; Hongyan Ding; Fangzhe Chen; Yanxin Zhao; Qi Yang; Qiang Dong
Journal:  Mol Neurobiol       Date:  2014-11-27       Impact factor: 5.590

5.  Dipyridamole Treatment Prior to Stroke Onset: Examining Post-stroke Cerebral Circulation and Outcome in Rabbits.

Authors:  Christopher D d'Esterre; Kenneth M Tichauer; Richard I Aviv; Wolfgang Eisert; Ting-Yim Lee
Journal:  Transl Stroke Res       Date:  2011-01-11       Impact factor: 6.829

6.  Early treatment with atorvastatin exerts parenchymal and vascular protective effects in experimental cerebral ischaemia.

Authors:  C Potey; T Ouk; O Petrault; M Petrault; V Berezowski; J Salleron; R Bordet; S Gautier
Journal:  Br J Pharmacol       Date:  2015-10-06       Impact factor: 8.739

7.  Rac1 is a critical mediator of endothelium-derived neurotrophic activity.

Authors:  Naoki Sawada; Hyung-Hwan Kim; Michael A Moskowitz; James K Liao
Journal:  Sci Signal       Date:  2009-03-10       Impact factor: 8.192

8.  Role of adenosine A2 receptors in regulation of cerebral blood flow during induced hypotension.

Authors:  Yoshikazu Kusano; German Echeverry; Greg Miekisiak; Tobias B Kulik; Shimon N Aronhime; Jiang F Chen; H Richard Winn
Journal:  J Cereb Blood Flow Metab       Date:  2009-11-18       Impact factor: 6.200

9.  Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury.

Authors:  Tobias Eckle; Kelly Hughes; Heidi Ehrentraut; Kelley S Brodsky; Peter Rosenberger; Doo-Sup Choi; Katya Ravid; Tingting Weng; Yang Xia; Michael R Blackburn; Holger K Eltzschig
Journal:  FASEB J       Date:  2013-04-19       Impact factor: 5.191

10.  Dipyridamole enhances ischaemia-induced arteriogenesis through an endocrine nitrite/nitric oxide-dependent pathway.

Authors:  Prasanna K Venkatesh; Christopher B Pattillo; Billy Branch; Jay Hood; Steven Thoma; Sandra Illum; Sibile Pardue; Xinjun Teng; Rakesh P Patel; Christopher G Kevil
Journal:  Cardiovasc Res       Date:  2010-01-08       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.